The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

PRESENTATION
Olanzapine/Samidorphan Combination (OLZ/SAM) for Patients With Schizophrenia or Bipolar I Disorder
Author(s):

Christoph U. Correll,1-3 Andrew J. Cutler,4,5 Rakesh Jain,6 Hemangi R. Panchmatia,7 Barry Lubarsky7

1Zucker Hillside Hospital, Glen Oaks, NY, USA; 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 3Charité Universitätsmedizin, Berlin, Germany; 4Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA; 5Neuroscience Education Institute, Lakewood Ranch, FL, USA; 6Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA; 7Alkermes, Inc., Waltham, MA, USA

Content available until 05/16/2029